Pfizer

NIVESTYM

Manufacturer:

Pfizer

Nivestym HCPCS:

Q5110

HCPCS Code Descriptor:

Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram

Category:

Q Code

Nivestym NDCs:

00069-0292-10, 00069-0294-10, 00069-0293-10, 00069-0291-10, 00069-0292-01, 00069-0291-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic/Specialty Status:

Single-Source

Route of Administration:

Injection

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Nivestym:

NIVESTYM is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Injection route of administration. The Q Code: Q5110 is aligned to the drug NIVESTYM.

Nivestym (pegfilgrastim) is an artificial protein that aids the production of white blood cells (neutrophils). Nivestym is manufactured by Pfizer and is biosimilar to the drug Neupogen (J1442). This drug has one HCPCS code, Q5110 that has been aligned to the medication since October 2018. Patient assistance programs for this medication can be found through Pfizer RxPathways.

ACCESS PRICING AND MORE BY REGISTERING

Q5110 Added Date:

October 1, 2018

Q5110 Effective Date:

October 1, 2018

Q5110 Termination Date:

HCPCS Active

Nivestym billing and coding information can be found through Pfizer at the link below:
Nivestym patient assistance information can be found through Pfizer Rx Pathways at the URL: http://www.pfizerrxpathways.com/
NIVESTYM prescribing information can be found at the link below:
Information regarding NIVESTYM’s side effects can be found at MedlinePlus